According to Zacks, “Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. Teva expects 2019 to be a tough year followed by return to growth in 2020 based on new launches. Its newest drugs, Austedo and Ajovy could emerge as significant contributors to long-term sales growth. However, despite impressive progress on restructuring activities, signs of stabilization in U.S. generic business and a more stable financial position than before, we believe the company has a long way to go before it gains stability. Resumption of organic growth seems unlikely until 2020. Teva’s shares have underperformed the generic industry this year so far. Estimates have gone down slightly ahead of Q1 earnings release. Teva has a mixed record of earnings surprises.”
Several other equities research analysts have also commented on TEVA. ValuEngine lowered Teva Pharmaceutical Industries from a buy rating to a hold rating in a research note on Wednesday, January 2nd. Bank of America raised Teva Pharmaceutical Industries from an underperform rating to a buy rating and set a $16.12 price target on the stock in a research note on Thursday, January 3rd. UBS Group raised Teva Pharmaceutical Industries from a neutral rating to a buy rating in a research note on Wednesday, January 23rd. Piper Jaffray Companies raised Teva Pharmaceutical Industries from an underweight rating to a neutral rating and boosted their price target for the stock from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Finally, HSBC set a $12.00 target price on Teva Pharmaceutical Industries and gave the company a sell rating in a research note on Tuesday, February 5th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of Hold and a consensus price target of $20.84.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, February 13th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The business had revenue of $4.56 billion for the quarter, compared to analyst estimates of $4.52 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.57% and a negative net margin of 11.40%. The company’s quarterly revenue was down 15.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.93 EPS. Analysts expect that Teva Pharmaceutical Industries will post 2.3 EPS for the current fiscal year.
In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 4,107 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $69,326.16. Following the transaction, the insider now owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Richard Daniell sold 2,098 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $35,414.24. Following the transaction, the vice president now directly owns 2,098 shares in the company, valued at approximately $35,414.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,691 shares of company stock worth $283,458. 0.49% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Northstar Group Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 34.9% during the 4th quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock worth $239,000 after purchasing an additional 4,000 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in shares of Teva Pharmaceutical Industries by 3.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 49,181 shares of the company’s stock worth $758,000 after purchasing an additional 1,681 shares during the period. Cacti Asset Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 12.5% during the 4th quarter. Cacti Asset Management LLC now owns 577,904 shares of the company’s stock worth $8,911,000 after purchasing an additional 64,180 shares during the period. AGF Investments America Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock worth $930,000 after purchasing an additional 1,458 shares during the period. Finally, Boston Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 18.0% during the 4th quarter. Boston Advisors LLC now owns 23,555 shares of the company’s stock worth $363,000 after purchasing an additional 3,592 shares during the period. 67.24% of the stock is currently owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.